Results 11 to 20 of about 8,733,364 (311)

Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation. [PDF]

Cells
Drug-induced cardiotoxicity (DICT) severely hampers drug development and threatens patient safety. Together with the growing global burden of cardiovascular disease, there is an urgent need to establish more predictive preclinical models. Recently, human
Chen M, Zhang T, Yang S, Niu Y, Ge Y, Chen Z, Zhang J, Pu Y, Gu Z, Liang G.   +9 more
europepmc   +3 more sources

Advances in preclinical evaluation of experimental antibody-drug conjugates [PDF]

Cancer Drug Resistance, 2021
The ability to chemically modify monoclonal antibodies with the attachment of specific functional groups has opened up an enormous range of possibilities for the targeted treatment and diagnosis of cancer in the clinic. As the number of such antibody-based drug candidates has increased, so too has the need for more stringent and robust preclinical ...
Lyons, Scott K., Plenker, Dennis, Trotman, Lloyd C.   +2 more
openaire   +4 more sources

Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation

Pharmaceutics, 2022
Drug-induced cardiotoxicity not only leads to the attrition of drugs during development, but also contributes to the high morbidity and mortality rates of cardiovascular diseases. Comprehensive testing for proarrhythmic risks of drugs has been applied in
Xiaoli Tang, Zengwu Wang, Shengshou Hu, Bingying Zhou   +3 more
doaj   +2 more sources

IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation [PDF]

Biomolecules & Biomedicine, 2022
Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research.
Yipeng Xu, Gabriela Pachnikova, He Wang, Yaoyao Wu, Dorothea Przybilla, Reinhold Schäfer, Zihao Chen, Shaoxing Zhu, Ulrich Keilholz   +8 more
doaj   +2 more sources

EXPERT EVALUATION OF PRECLINICAL STUDIES OF PRIMARY AND SECONDARY PHARMACODYNAMICS OF MEDICINES [PDF]

Регуляторные исследования и экспертиза лекарственных средств, 2018
The article dwells upon the results of comparative analysis of the Russian national requirements  and EAEU regulations dealing with evaluation of preclinical pharmacological studies.
G. N. Engalycheva, R. D. Subaev, D. V. Gorachev, Yu. V. Olefir   +3 more
doaj   +2 more sources

P2X7 Receptor Agonist 2′(3′)-O-(4-Benzoylbenzoyl)ATP Differently Modulates Cell Viability and Corticostriatal Synaptic Transmission in Experimental Models of Huntington’s Disease

Frontiers in Pharmacology, 2021
Huntington’s disease (HD) is a life-threatening neurodegenerative disorder. Altered levels and functions of the purinergic ionotropic P2X7 receptors (P2X7Rs) have been found in animal and cellular models of HD, suggesting their possible role in the ...
Alberto Martire, Rita Pepponi, Francesco Liguori, Cinzia Volonté, Cinzia Volonté, Patrizia Popoli   +5 more
doaj   +1 more source

Lychee seed polyphenol protects blood–retinal barrier by increasing tight joint proteins and inhibiting the activation of TLR4/MYD88/NF-κB-mediated NLRP3 inflammasome

Food and Agricultural Immunology, 2021
Emerging evidence indicates that blood–retinal barrier (BRB) damage is the main cause of diabetic retinopathy (DR), and the downregulation of tight proteins (TJs) located between endothelial cells and the activation of NLRP3 inflammasome-mediated ...
Jing Wei, Xiao-Hong Xiang, Yong Tang, Da-Lian Qin, Jian-Ming Wu, Chong-Lin Yu, Wen-Qiao Qiu, An-Guo Wu, Hong-Bin Lv   +8 more
doaj   +1 more source

Application of Genomics in Preclinical Drug Safety Evaluation [PDF]

Basic & Clinical Pharmacology & Toxicology, 2006
Abstract: Understanding the response of biological systems to xenobiotics is fundamental to the evaluation of drug safety. Toxicologists have traditionally gathered pathological, morphological, chemical and biochemical information from in vivo studies of preclinical species in order to assess drug safety and to determine how new drugs can be safely ...
Peter G, Lord, Alex, Nie, Michael, McMillian   +2 more
openaire   +2 more sources

Irreproducibility –The deadly sin of preclinical research in drug development [PDF]

, 2020
Introduction. In recent years the irreproducibility of preclinical studies has become a serious concern in drug developmental research. The findings of preclinical studies that cannot be reproduced are a drain on public resources and slow down the drug ...
Arumugam, M., Kobayashi, K., Pillai, S.K., Michael, M., Sadasivan Pillai, Sadasivan Kalathil Pillai, Katsumi Kobayashi, Meena Arumugam, Mathews Michael, Meena A   +9 more
core   +1 more source

Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors

, 2022
Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing ...
Jeff Hooley (15084369), Ying Li (15092440), Richard J. Gregory (15092479), Stuart W. Hicks (15092404), Marian Themeles (15092434), Jacquelynn Lucas (15092419), Kerstin W. Sinkevicius (15092407), Kerry A. McEachem (15092464), Nicholas C. Yoder (15092410), Valentina Ciccarone (15092461), Sergey Gorlatov (15092455), Paul A. Moore (15092473), Deryk Loo (15092485), Megan E. Fuller (15092422), Thomas Son (15092425), Lusiana Widjaja (15092452), Olga Ab (15087715), Thomas Chittenden (15092476), Francine Z. Chen (15092437), James Tamura (15092458), Bhaswati Barat (15092449), Scott Koenig (15092467), Michael Chiechi (15092443), Christopher Espelin (15092431), Jennifer G. Brown (15092416), Gundo Diedrich (15092413), Juniper A. Scribner (15092401), Jenny Lee (15092446), Ezio Bonvini (15092482), Anahita Dastur (15092428), Eric H. Westin (15092470)   +30 more
core   +1 more source